Medivive

Pharmaceuticals

Our prefilled NAD+ injector pen is the first of its kind in the United States, delivering 1,000 mg of pharmaceutical-grade, preservative-free NAD+.

Services
  • NAD+ Injector Pen
  • Electronic prescriptions
  • Direct-to-patient fulfillment
Location San Diego, CA
About

Medivive

Medivive was built around a simple idea: NAD+ therapy should be accessible, consistent, and easy to prescribe. Our prefilled NAD+ injector pen is the first of its kind in the United States, delivering 1,000 mg of pharmaceutical-grade, preservative-free NAD+ in a format that patients can self-administer at home.

NAD+ is a central metabolic cofactor involved in over 500 enzymatic reactions, including DNA repair via PARPs and metabolic regulation through sirtuins. Tissue levels decline significantly with age, and restoring them has shown meaningful effects on energy, cognitive clarity, and cellular resilience. Subcutaneous delivery provides near-complete bioavailability and a sustained-release profile, avoiding the rapid spike and drop associated with IV administration.

Our pen is manufactured by VeV Scientific, an FDA-registered 503B outsourcing facility in San Diego operating under cGMP standards in an ISO-certified cleanroom. Dispensing is handled by Chemistry Rx, a PCAB-accredited, LegitScript-certified 503A pharmacy. Every pen ships cold-chain via FedEx directly to the patient, so practices carry zero inventory and take on no logistics burden.

For providers, prescribing takes under two minutes through our online portal. All supplies are included, patient onboarding is handled by our team, and auto-refill keeps patients on protocol without extra work for your staff. The pen creates meaningful recurring revenue while offering patients a more convenient and affordable alternative to IV NAD+ sessions.

We built Medivive for clinicians who take cellular medicine seriously and want a reliable, compliant way to integrate NAD+ into their practice. No vials, no syringes, no guesswork. Just a better way to deliver NAD+.

Unlock exclusive discounts and offers from Medivive and other trusted partners with an SSRP Pro Membership.
What People Say

Testimonials

Now, we can feel more confident in measuring and following the evidence on this with a safe product…this really opens the door to some powerful things you can start doing as you work to help that patient. I mean, it’s things that I have not been able to do for a very long time.

-This quote was originally shared on the Redox Revolution Podcast Episode 50

Dr. William Seeds Founder and Academic Chairman SSRP Institute

The feedback we have from customers and patients is that they love the ease of use… patients stating that they sleep much better, much better mental clarity, better energy levels.

Damien Hancox CEO SpectrumX
Network with our partners

Upcoming Events

View Upcoming Events
EVENT
Grand Rounds
December 4 - 5, 2026

Grand Rounds

Coming Soon
RESOURCES

Join us in breaking down the latest research live.

VIEW ALL
PODCAST
Redox Revolution
Oct 13, 2026
Ep.81 – The Crossover Between Cellular Medicine and Regenerative Aesthetics with Angel Channell
Ep.81 – The Crossover Between Cellular Medicine and Regenerative Aesthetics with Angel Channell

In this episode of Redox Revolution, Dr. Seeds sits down with aesthetician Angela Channel to discuss her approach not only to skin care but overall holistic healing.

Cellular Medicine Foundations
VIDEO
Cellular Medicine Mondays
Oct 12, 2026
Ep. 109 - Anti-Ageing Mini Mastermind Part 2
Preview only
Journal Club – Episode 109

Anti-Aging Mini Mastermind Part 2

In Part 2 of our Anti-Aging Mini Mastermind series, Dr. Seeds explores how PGE2 signaling and cellular metabolism influence inflammation, cognitive function, and aging, connecting foundational research to emerging discoveries in immunometabolism.  (2026 Article) (2021 Article)

Preview Only — Become a member for full access
ARTICLE
William Seeds, MD
Oct 8, 2026
EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging
William Seeds, MD Oct 8, 2026
EP2, Tissue-Resident Macrophages, and a New Mechanism of Organ Aging
Revisiting a Journal Club Article, “Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging.” Science. 2026  Why This Paper Matters Most of the senescence conversation over the past decade has centered on a familiar cast: senescent fibroblasts, endothelial cells, adipocytes, and the drugs designed to clear them. This paper, which I discuss in […]
READ ARTICLE
Healthgevity Oct 2, 2026
Healthgevity Introduces hydraCELL+â„¢, Featuring Formulation IP Developed by the Seeds Foundation for Cellular Research
BREAKING NEWS INTERLAKEN, N.J., [October 2, 2026] — Healthgevity, a practitioner-focused precision longevity nutrition company, announced the launch of hydraCELL+â„¢, a cellular hydration and muscle-support formula built on proprietary formulation IP developed through the Seeds Foundation for Cellular Research and licensed to Healthgevity. The formula reflects the cellular medicine approach advanced by William Seeds, MD, and […]
READ NEWS
ARTICLE
William Seeds, MD
Sep 23, 2026
The Future of Regenerative Medicine May Begin with a Hair Follicle
William Seeds, MD Sep 23, 2026
The Future of Regenerative Medicine May Begin with a Hair Follicle
Why a Plucked Hair Follicle May Matter to the Future of Regenerative Medicine In this article, I return to a study that I discussed in a July Journal Club post. The study, published in Cells in 2024, investigated whether cells obtained from plucked, cryopreserved human hair follicles could be reprogrammed into induced pluripotent stem cells […]
READ ARTICLE
Peptide Therapy Certification 2026
The SSRP Peptide Therapy Certification course gives clinicians, researchers, and other healthcare providers a working method for applying Cellular Medicine principles to patient care through clinical peptide therapy. Across 19 faculty-led lessons, Dr. William Seeds and SSRP faculty, including Siobhan...
19 Lessons
15 hrs 43 min
View Course
SSRP Institute Sep 14, 2026
In Case You Missed it: FDA Approves Mounjaro (tirzepatide) for CVD
HEADLINE SCIENCE [Sept 14, 2026] – On August 28, 2026, the FDA expanded the indication for Mounjaro (tirzepatide), approving the dual GIP/GLP-1 receptor agonist to reduce the risk of major adverse cardiovascular events—including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—in adults with type 2 diabetes at high cardiovascular risk. The decision makes tirzepatide the […]
READ NEWS
EVENT
Certification
September 10 - 11, 2027
Peptide Therapy Certification 2027
Four Seasons Resort Orlando at Walt Disney World, FL
COMING SOON
Certification
Peptide Therapy Certification 2027
COMING SOON
EVENT
World Congress
June 17 - 19, 2027
Peptide World Congress 2027
Arizona Biltmore, Phoenix, AZ
COMING SOON
World Congress
Peptide World Congress 2027
COMING SOON
EVENT
Mastermind
February 15 - 19, 2027
Fellowship Mastermind Summit 2027
Gansevoort Meatpacking NYC, New York, NY
COMING SOON
Mastermind
Fellowship Mastermind Summit 2027
COMING SOON
EVENT
Grand Rounds
December 4 - 5, 2026
Grand Rounds
Four Seasons Resort and Residences Vail
COMING SOON
Grand Rounds
Grand Rounds
COMING SOON
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
HEADLINE SCIENCE [August 27, 2026] – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS